Menu
Equities By Region UK Pharmaceuticals & Health

GSK share price: Pharmco wraps up Consumer Healthcare buyout

Share this article!

GlaxoSmithKline (LON:GSK) has completed the buyout of Novartis’ stake in their Consumer Healthcare joint venture, the London-listed pharmco has said. The companies announced the deal in March this year.

GSK’s share price has gained ground in London in today’s session, having added 0.43 percent to 1,530.60p as of 13:27 BST. The stock is marginally underperforming the broader UK market, with the benchmark FTSE 100 index currently standing 0.72 percent higher at 7,733.67 points. The pharmco’s shares have lost a little over 10 percent of their value over the past year, as compared with about a 2.5-percent rise in the Footsie.

GSK wraps up Consumer Healthcare deal

GSK announced in a statement today that it had completed the buyout of Novartis’ 36.5-percent stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion). The move came after shareholders okayed the deal on May 3.

The UK group unveiled the deal in March this year, explaining at the time that it addressed its key capital allocation priorities, supporting efforts to improve performance and capital planning. The blue-chip drugmaker further kicked off a review of its Horlicks business, saying that it expected to conclude it around the end of the year.

Today’s announcement comes after GSK recently inked a deal to divest its rare disease gene therapy portfolio to Orchard Therapeutics.

Analysts on blue-chip drugmaker

JPMorgan Chase & Co, which sees GSK as a ‘neutral,’ set a price target of 1,500p on the shares yesterday, while last week, UBS, which has a ‘buy’ rating on the blue-chip drugmaker, set a valuation of 1,600p on the stock. According to MarketBeat, the FTSE 100 group currently has a consensus ‘hold’ rating and an average price target of 1,547.14p.

As of 13:50 BST, Friday, 01 June, GlaxoSmithKline plc share price is 1,526.80p.

Add Comment

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.